Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Dec;70(6):1188–1190. doi: 10.1038/bjc.1994.471

Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.

P Venesmaa 1, P Lehtovirta 1, U H Stenman 1, A Leminen 1, M Forss 1, O Ylikorkala 1
PMCID: PMC2033663  PMID: 7981075

Abstract

We have evaluated the prognostic value of tumour-associated trypsin inhibitor (TATI) in stage III or IV ovarian cancer. Tumour-associated trypsin inhibitor (TATI) and CA 125 were determined in serum samples from 66 patients taken before primary surgery. TATI was elevated (> 22 micrograms l-1) in 27 patients (41%). These had a 5 year cumulative survival of 8%, whereas survival was 45% in 39 patients with normal preoperative TATI values. By contrast, the preoperative CA 125 level did not predict survival. In multivariate analysis which included age, stage, histological grade and preoperative TATI and CA 125 levels, patients with elevated preoperative TATI levels had a 2.3-fold relative risk of death (95% confidence interval 1.23-4.20; P = 0.002) compared with patients with normal preoperative levels. This result was comparable with the predictive value of primary residual tumour size, since patients with residual tumour larger than 2 cm in diameter had a 5.2-fold relative risk of death (95% confidence interval 2.55-10.68) compared with patients with a smaller or no residual tumour. Thus, preoperative determination of serum TATI may have a place in the pretreatment evaluation of patients with advanced ovarian cancer.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  2. Halila H., Lehtovirta P., Stenman U. H. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer. 1988 Mar;57(3):304–307. doi: 10.1038/bjc.1988.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Halila H., Stenman U. H., Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer. 1986 Apr 1;57(7):1327–1329. doi: 10.1002/1097-0142(19860401)57:7<1327::aid-cncr2820570713>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  4. Huhtala M. L., Kahanpä K., Seppälä M., Halila H., Stenman U. H. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer. 1983 Jun 15;31(6):711–714. doi: 10.1002/ijc.2910310606. [DOI] [PubMed] [Google Scholar]
  5. Koivunen E., Huhtala M. L., Stenman U. H. Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem. 1989 Aug 25;264(24):14095–14099. [PubMed] [Google Scholar]
  6. Koivunen E., Ristimäki A., Itkonen O., Osman S., Vuento M., Stenman U. H. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res. 1991 Apr 15;51(8):2107–2112. [PubMed] [Google Scholar]
  7. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C., Jr CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb;69(2):223–227. [PubMed] [Google Scholar]
  8. Makar A. P., Kristensen G. B., Kaern J., Børmer O. P., Abeler V. M., Tropé C. G. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992 Jun;79(6):1002–1010. [PubMed] [Google Scholar]
  9. Mogensen O., Mogensen B., Jakobsen A. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol. 1990 Aug;38(2):170–174. doi: 10.1016/0090-8258(90)90035-j. [DOI] [PubMed] [Google Scholar]
  10. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992 Mar;44(3):207–212. doi: 10.1016/0090-8258(92)90043-i. [DOI] [PubMed] [Google Scholar]
  11. Rosen A., Sevelda P., Klein M., Spona J., Beck A. A CA125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet. 1990;247(3):125–129. doi: 10.1007/BF02390860. [DOI] [PubMed] [Google Scholar]
  12. Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Nov;161(5):1213–1216. doi: 10.1016/0002-9378(89)90668-6. [DOI] [PubMed] [Google Scholar]
  13. Stenman U. H., Huhtala M. L., Koistinen R., Seppälä M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer. 1982 Jul 15;30(1):53–57. doi: 10.1002/ijc.2910300110. [DOI] [PubMed] [Google Scholar]
  14. Stenman U. H., Koivunen E., Itkonen O. Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest Suppl. 1991;207:5–9. doi: 10.3109/00365519109104618. [DOI] [PubMed] [Google Scholar]
  15. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES